This webcast features: Gareth Meek-Brown, Lead Scientist, Lonza Biologics – Slough
Product Quality assessment during Upstream and Downstream Process Development is key to the production of safe and efficacious biopharmaceuticals.
Critical quality attributes such as N-linked glycosylation are highly dependent upon biosynthesis conditions and play a crucial role in the pharmacology of therapeutic proteins, potentially affecting immunogenicity, pharmacokinetics and pharmacodynamics.
The presence of N-linked glycosylation has benefits including increased thermal, physical and chemical stability over aglycosylated variants. The optimum N-linked glycosylation profile will depend on the desired target effect of the therapeutic protein in question. The effect glycosylation has on biopharmaceutical activity highlights the need to identify glycosylation expression during process development where expression can be altered.
N-linked and O-linked are the most common types of glycosylation. In this webinar we present the use of High Throughput N-linked glycosylation sample preparation and analysis by LC-MS to screen high numbers of potential clones for cell line selection and upstream process development.